6 completed, 5 terminated, 5 unknown, 4 not yet recruiting. 14 Phase 2, 6 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Terminated 4, Unknown 4, Completed 3, Not yet recruiting 3 |
| Phase 3 | 6 | Not yet recruiting 2, Terminated 2, Completed 1, Recruiting 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
Follow tegafur-gimeracil-oteracil: new trials by email Literature Review of tegafur-gimeracil-oteracil trials Research Report on tegafur-gimeracil-oteracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin - Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 34 | 2026-11-01 | 2026-09-18 |
| Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study Zanidatamab, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Zhifeng Zhao, PhD | 46 | 2026-07-01 | 2026-07-06 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Not yet recruiting | J. W. A. Burger | 394 | 2026-03-03 | 2026-03-16 |
| Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib, Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen) - Biliary Tract Cancer, Second Line Treatment | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 206 | 2024-11-25 | 2024-10-29 |
| Study of Comparing of With and Without Sequential Therapy of S-1 Docetaxel, Tegafur-Gimeracil-Oteracil - Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect | Phase 3 | Recruiting | Zhejiang University | 70 | 2023-01-28 | 2023-04-14 |
| A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE) - Gastric Cancer | Phase 1 | Unknown | Shanghai Zhongshan Hospital | 20 | 2022-06-01 | 2022-05-31 |
| Neoadjuvant TACiE in Locally Advanced Gastric Cancer Oxaliplatin, Teysuno, Transarterial chemoembolization (TACE) - Gastric Cancer | Phase 2 | Unknown | Shanghai Zhongshan Hospital | 37 | 2022-06-01 | 2022-05-26 |
| Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab - Stomach Neoplasms, Esophagogastric Junction Disorder | Phase 2 | Terminated | Fudan University | 6 | 2021-09-28 | 2025-06-18 |
| Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer Nivolumab, Gemcitabine, Tegafur-Gimeracil-Oteracil - Stage IV Pancreatic Cancer | Phase 2 | Unknown | National Taiwan University Hospital | 38 | 2020-07-01 | 2020-05-06 |
| Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis Tegafur-Gimeracil-Oteracil - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 220 | 2018-12-14 | 2021-06-23 |
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study Fluoropyrimidine - Solid Tumor | Enrolling by invitation | Helsinki University Central Hospital | 200 | 2018-06-01 | 2024-12-12 | |
| Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction S-1 - Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction | Phase 1 / Phase 2 | Completed | AIO-Studien-gGmbH | 30 | 2015-10-06 | 2021-04-29 |
| S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy S-1 (452500ACH), OXALIPLATIN (205803BIJ) - Stomach Cancer | Phase 2 | Terminated | Kangbuk Samsung Hospital | 8 | 2015-05-01 | 2022-12-08 |
| Effects of S-1 and Capecitabine on Coronary Artery Blood Flow S-1, Capecitabine, Oxaliplatin - Esophagus Cancer, Stomach Cancer | Phase 2 | Terminated | Heikki Joensuu | 20 | 2015-01-01 | 2018-08-28 |
| Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer S-1 and Oxaliplatin - Esophageal Cancer | Phase 1 | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 40 | 2014-12-01 | 2019-11-18 |
| Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer S-1 de-escalation, Chemotherapy by Investigator's choice - Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm | Phase 2 | Completed | AIO-Studien-gGmbH | 242 | 2014-09-01 | 2021-03-26 |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Teysuno, Capecitabine - Gastrointestinal Cancer, Cancer of Unknown Primary Site | Phase 2 | Completed | University of Edinburgh | 59 | 2014-02-05 | 2023-05-12 |
| S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. Capecitabine, Teysuno, Bevacizumab - Colorectal Cancer, Metastases | Phase 3 | Completed | Dutch Colorectal Cancer Group | 161 | 2013-12-01 | 2018-03-14 |
| Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer S-1 and Paclitaxel, Paclitaxel and Cisplatin, 5-FU and Cisplatin - Esophageal Cancer | Phase 2 / Phase 3 | Terminated | Peking University | 4 | 2012-08-01 | 2017-04-07 |
| Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer S-1 plus oxaliplatin - Gastrointestinal Cancer | Phase 2 | Unknown | Xijing Hospital | 200 | 2012-03-01 | 2012-05-31 |
Showing 20 of 22. Sign in to see all of them.
Stomach Neoplasms (8) · Esophageal Neoplasms (4) · Gastrointestinal Neoplasms (3) · Adenocarcinoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hand-Foot Syndrome (1) · Nasopharyngeal Carcinoma (1) · Neoplasms, Unknown Primary (1) · Pathologic Complete Response (1)
AIO-Studien-gGmbH (2) · Shanghai Zhongshan Hospital (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Disphar International B.V. (1) · Dutch Colorectal Cancer Group (1) · Fudan University (1) · Heikki Joensuu (1) · Helsinki University Central Hospital (1) · J. W. A. Burger (1) · Kangbuk Samsung Hospital (1) · National Taiwan University Hospital (1) · Peking University (1) · Sun Yat-sen University (1) · Taiho Oncology, Inc. (1) · The First Affiliated Hospital of Zhengzhou University (1)
China (9) · Netherlands (4) · Germany (3) · Finland (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Croatia (1) · Denmark (1) · Estonia (1) · Hungary (1) · Iceland (1) · Ireland (1)
Cornelis JA Punt, Prof MD PhD (1) · Dong Hoe Koo, MD,PhD (1) · Georg Martin Haag, Dr. (1) · H WM van Laarhoven, MD,PHD,PHD (1) · Heikki Joensuu, MD (1) · Jacobus WA Burger, Prof. dr. (1) · Jianjun Yang, Prof. (1) · Sally Clive, MBChB (1) · Shih-Hung Yang, M.D., Ph.D. (1) · Taiho Central (1) · Volker Heinemann, Prof. Dr. (1) · Xiaodong Zhang, MD (1)
PMID 23547081, PMID 28383633, PMID 28760152, PMID 28911091, PMID 29119276, PMID 30782413, PMID 35764956, PMID 35798468, PMID 37270871, PMID 41113977, PMID 42151882
2014 (1), 2025 (1)